TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities
CNS Pharmaceuticals (NASDAQ: CNSP), a Texas-based cancer drug innovator, is focused on advancing its potentially pivotal clinical trial to track the effectiveness of drug candidate Berubicin in treating glioblastoma (“GBM”) brain cancers. Berubicin has already produced one patient with over 15 years of GBM survival. “Berubicin distinguishes itself by being virtually unique in its status as a cancer-fighting anthracycline that crosses the blood-brain barrier to attack central nervous system tumors directly. Berubicin also distinguished itself by presenting statistically significant improvement in nearly half of the two dozen patients evaluated in a phase I trial in 2006, including one patient whose…

